These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21068144)

  • 1. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.
    Lu H; Yang Y; Gad E; Wenner CA; Chang A; Larson ER; Dang Y; Martzen M; Standish LJ; Disis ML
    Clin Cancer Res; 2011 Jan; 17(1):67-76. PubMed ID: 21068144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
    Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
    Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.
    Engel AL; Sun GC; Gad E; Rastetter LR; Strobe K; Yang Y; Dang Y; Disis ML; Lu H
    Immunobiology; 2013 Dec; 218(12):1468-76. PubMed ID: 23735481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan.
    Quayle K; Coy C; Standish L; Lu H
    J Nat Med; 2015 Apr; 69(2):198-208. PubMed ID: 25510899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polysaccharide-K (PSK) increases p21(WAF/Cip1) and promotes apoptosis in pancreatic cancer cells.
    Rosendahl AH; Sun C; Wu D; Andersson R
    Pancreatology; 2012; 12(6):467-74. PubMed ID: 23217280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK.
    Suo J; Tanaka N; Hizuta A; Yunoki S; Orita K
    Acta Med Okayama; 1994 Oct; 48(5):237-42. PubMed ID: 7863794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Krestin (PSK).
    Tsukagoshi S; Hashimoto Y; Fujii G; Kobayashi H; Nomoto K; Orita K
    Cancer Treat Rev; 1984 Jun; 11(2):131-55. PubMed ID: 6238674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice.
    Harada M; Matsunaga K; Oguchi Y; Iijima H; Tamada K; Abe K; Takenoyama M; Ito O; Kimura G; Nomoto K
    Int J Cancer; 1997 Jan; 70(3):362-72. PubMed ID: 9033641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.
    Inatsuka C; Yang Y; Gad E; Rastetter L; Disis ML; Lu H
    Cancer Immunol Immunother; 2013 Aug; 62(8):1335-45. PubMed ID: 23685781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.
    Koido S; Homma S; Okamoto M; Namiki Y; Takakura K; Takahara A; Odahara S; Tsukinaga S; Yukawa T; Mitobe J; Matsudaira H; Nagatsuma K; Uchiyama K; Kajihara M; Arihiro S; Imazu H; Arakawa H; Kan S; Komita H; Ito M; Ohkusa T; Gong J; Tajiri H
    PLoS One; 2013; 8(3):e59280. PubMed ID: 23555011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.
    Kariya Y; Inoue N; Kihara T; Okamoto N; Sugie K; Mori T; Uchida A
    Immunol Lett; 1992 Feb; 31(3):241-5. PubMed ID: 1372283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells, macrophages, NK and CD8
    Lucinda N; Figueiredo MM; Pessoa NL; Santos BS; Lima GK; Freitas AM; Machado AM; Kroon EG; Antonelli LR; Campos MA
    Virol J; 2017 Feb; 14(1):37. PubMed ID: 28222752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSK as a chemopreventive agent.
    Kobayashi H; Matsunaga K; Fujii M
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):271-6. PubMed ID: 8318880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antitumor effect of intratumoral administration of a Coriolus preparation, PSK: inhibition of tumor invasion in vitro].
    Ebina T; Murata K
    Gan To Kagaku Ryoho; 1994 Sep; 21(13):2241-3. PubMed ID: 7944450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
    Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
    Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
    Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
    Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones.
    Algarra I; Collado A; Garrido F
    J Exp Clin Cancer Res; 1997 Dec; 16(4):373-80. PubMed ID: 9505208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of PSK at a distant site: inductions of interleukin-8-like factor and macrophage chemotactic factor in murine tumor.
    Ebina T; Murata K
    Jpn J Cancer Res; 1990 Dec; 81(12):1307-13. PubMed ID: 2126000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses.
    Chandran SS; Verhoeven D; Teijaro JR; Fenton MJ; Farber DL
    J Immunol; 2009 Dec; 183(12):7832-41. PubMed ID: 19933854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
    Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
    Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.